We demonstrated in this study that the MSLN-targeted fusion protein elicited significant tumor-specific CD8+ T-cell immune responses in ovarian cancer-bearing mice, and this adaptive antitumor response has an absolute requirement for tumor-specific CD8+ T cells. Here, CD8A is linked to ovarian carcinoma.